NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA)…Original Article
FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
